64935b9c-623d-40d4-bd89-f2af006b1f92
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 51
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.520
- MYC_TARGETS_V2+0.480
- OXIDATIVE_PHOSPHORYLATION+0.430
- MYC_TARGETS_V1+0.410
- G2M_CHECKPOINT+0.400
- DNA_REPAIR+0.310
- SPERMATOGENESIS+0.270
- MTORC1_SIGNALING+0.240
- UNFOLDED_PROTEIN_RESPONSE+0.240
- MITOTIC_SPINDLE+0.230
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.650
- INFLAMMATORY_RESPONSE-0.540
- INTERFERON_GAMMA_RESPONSE-0.510
- ALLOGRAFT_REJECTION-0.480
- NOTCH_SIGNALING-0.480
- INTERFERON_ALPHA_RESPONSE-0.470
- ANGIOGENESIS-0.440
- IL6_JAK_STAT3_SIGNALING-0.430
- TNFA_SIGNALING_VIA_NFKB-0.420
- COMPLEMENT-0.410
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-DK-A3X2-01A-11R-A22U-07 | — | — | 0.950 |
| 2 | 513fb61a-1339-45d2-8963-6337e3aff5df | — | — | 0.948 |
| 3 | a8ce7460-8ccd-4638-a854-55c4068af6ec | — | — | 0.944 |
| 4 | AUR-AFR3-TTM1-A-1-1-R-A743-41 | — | C | 0.944 |
| 5 | SRR975602 | — | — | 0.940 |
| 6 | TCGA-51-4080-01A-01R-1100-07 | — | cohortSQ2 | 0.934 |
| 7 | ERR2208894 | — | — | 0.933 |
| 8 | BS_NKEAAFMW | medulloblastoma | — | 0.932 |
| 9 | SRR8518295 | — | E | 0.930 |
| 10 | TCGA-60-2719-01A-01R-0851-07 | — | cohortSQ1 | 0.928 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.520 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.480 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.430 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.410 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.310 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.270 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.240 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.240 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.230 | Inavolisib | — uncovered |
| PEROXISOME | 0.210 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.130 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.120 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.090 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.080 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.030 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.020 | Inavolisib | — uncovered |